There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...
Please provide your email address to receive an email when new articles are posted on . Almost all of the estimated 1.15 MMT of CO 2 equivalent emissions in 2022 came from metered-dose inhalers. The ...
The researchers evaluated budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol in preventing COPD exacerbations and pneumonia hospitalizations in real-world settings. They ...
Please provide your email address to receive an email when new articles are posted on . “Many health care systems are discussing a transition to dry-powder inhalers that have a lower carbon footprint ...
Those receiving budesonide-glycopyrrolate-formoterol compared with fluticasone-umeclidinium-vilanterol had a higher risk for a first moderate COPD exacerbation. William B. Feldman, MD, MPH, from ...
PHILADELPHIA, June 1, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced the U.S. Food and Drug Administration (FDA) has accepted the Abbreviated New Drug Application (ANDA) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results